Analyst Benjamin Jackson CFA of Jefferies maintained a Buy rating on Galderma Group AG, retaining the price target of CHF160.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that highlight Galderma Group AG’s promising growth outlook. The company’s CFO, Thomas Dittrich, emphasized the 2025 guidance, which includes significant contributions from various product categories. Additionally, there is potential to unlock further US Nemluvio volumes from early 2026 through government channels, albeit with some pricing discounts.
Furthermore, the company plans to rapidly launch Relfydess in the US once approved, which is expected to drive further market share gains. Galderma’s strategic focus on mergers and acquisitions, alongside its expectation of achieving 17.0%-17.7% constant exchange rate net sales growth for 2025, supports a positive outlook. The anticipated acceleration of growth and progressive margin expansion, particularly through new product launches and market introductions, further solidifies the Buy rating.
In another report released on November 17, Barclays also maintained a Buy rating on the stock with a CHF155.00 price target.